Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
College of Preclinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
J Ethnopharmacol. 2022 Jan 30;283:114667. doi: 10.1016/j.jep.2021.114667. Epub 2021 Sep 29.
Induced vascular growth in the myocardium has been widely acknowledged as a promising intervention strategy for patients with ischemic coronary artery disease. Yet despite long-term efforts on gene, protein or cell-based pro-angiogenic therapies, the clinical translation remains challenging. Noticeably, multiple medicinal herbs have long-term documented effects in promoting blood circulation. Salvia miltiorrhiza and Ligusticum stratum are two representative traditional Chinese medicine herbs with suggested roles in enhancing organ blood supply, and Guanxinning Tablet (GXNT), a botanical drug which is formulated with these two herbs, exhibited significant efficacy against angina pectoris in clinical practices.
This study aimed to examine the pro-angiogenic activity of GXNT and its major components, as well as to explore their pharmacological mechanism in promoting angiogenesis.
In vitro, the pro-angiogenic effects of GXNT and its major components were examined on human umbilical vein endothelial cells by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT), scratch assay, and endothelial cell tube formation assay. In vivo, the pro-angiogenic effects were examined on the ponatinib-induced angiogenesis defective zebrafish model. The active compounds were identified through phenotype-based screening in zebrafish, and their pharmacological mechanism was explored in both in vitro and in vivo models by immunofluorescent staining, cell cycle analysis, quantitative PCR and whole embryo in-situ hybridization.
We demonstrated strong pro-angiogenic effects of GXNT in both human umbilical vein endothelial cells and zebrafish model. Moreover, through phenotype-based screening in zebrafish for active compounds, pro-angiogenic effects was discovered for salvianolic acid B (Sal B), a major component of Salvia miltiorrhiza, and its activity was further enhanced when co-administered with ferulic acid (FA), which is contained in Ligusticum stratum. On the cellular level, Sal B and FA cotreatment increased endothelial cell proliferation of sprouting arterial intersomitic vessels in zebrafish, as well as largely restored G1-S cell cycle progression and cyclin D1 expression in angiogenic defective HUVECs. Through quantitative transcriptional analysis, increased expression of vegfr2 (kdr, kdrl) and vegfr1 was detected after GXNT or SalB/FA treatment, together with upregulated transcription of their ligands including vegf-a, vegf-b, and pgfb. Bevacizumab, an anti-human VEGF-A monoclonal antibody, was able to significantly, but not completely, block the pro-angiogenic effects of GXNT or SalB/FA, suggesting their multi-targeting properties.
In conclusion, from a traditional Chinese medicine with effects in enhancing blood circulation, we demonstrated the synergistic pro-angiogenic effects of Sal B and FA via both in vitro and in vivo models, which function at least partially through regulating the expression of VEGF receptors and ligands. Future studies are warranted to further elaborate the molecular interaction between these two compounds and the key regulators in the process of neovascularization.
诱导心肌血管生长已被广泛认为是治疗缺血性冠状动脉疾病患者的一种有前途的干预策略。尽管在基因、蛋白质或基于细胞的促血管生成治疗方面进行了长期努力,但临床转化仍然具有挑战性。值得注意的是,许多草药在促进血液循环方面具有长期的记录效果。丹参和川芎是两种具有增强器官血液供应作用的代表性中药,以这两种草药为配方的冠心宁片(GXNT)在临床实践中对心绞痛表现出显著疗效。
本研究旨在研究 GXNT 及其主要成分的促血管生成活性,并探讨其促进血管生成的药理机制。
在体外,通过 3-(4,5-二甲基-2-噻唑基)-2,5-二苯基-2-H-四唑溴盐(MTT)、划痕试验和内皮细胞管形成试验,研究 GXNT 及其主要成分对人脐静脉内皮细胞的促血管生成作用。在体内,通过ponatinib 诱导的血管生成缺陷斑马鱼模型研究促血管生成作用。通过斑马鱼基于表型的筛选鉴定活性化合物,并通过免疫荧光染色、细胞周期分析、定量 PCR 和全胚胎原位杂交在体外和体内模型中探讨其药理机制。
我们证明了 GXNT 在人脐静脉内皮细胞和斑马鱼模型中均具有很强的促血管生成作用。此外,通过斑马鱼基于表型的筛选寻找活性化合物,发现丹参中的主要成分丹参酸 B(Sal B)及其活性成分阿魏酸(FA)具有促血管生成作用,两者联合使用可进一步增强活性。在细胞水平上,Sal B 和 FA 共处理可增加斑马鱼中动脉体节间血管的内皮细胞增殖,并在血管生成缺陷的 HUVECs 中大大恢复 G1-S 细胞周期进程和细胞周期蛋白 D1 的表达。通过定量转录分析,发现 GXNT 或 SalB/FA 处理后 vegfr2(kdr、kdrl)和 vegfr1 的表达增加,同时其配体包括 vegf-a、vegf-b 和 pgfb 的转录也上调。贝伐单抗,一种抗人类 VEGF-A 单克隆抗体,能够显著但不完全阻断 GXNT 或 SalB/FA 的促血管生成作用,表明它们具有多靶点特性。
总之,从一种具有增强血液循环作用的中药中,我们通过体外和体内模型证明了 Sal B 和 FA 的协同促血管生成作用,其作用至少部分通过调节 VEGF 受体和配体的表达来实现。需要进一步的研究来阐明这两种化合物与血管新生过程中的关键调节剂之间的分子相互作用。